why vir stock is down

Aside from the general weakness in the market, the recent decline in COVID-19 cases and hospitalizations appeared to have led to the recent selloff. Vir (NASDAQ: VIR) has lost more than a third of its value so far in the year, while GlaxoSmithKline (GSK -2.2%) its partner for sotrovimab has dropped ~3%.

Full Answer

Is Vir Biotechnology,Inc.(Vir) stock on the verge of a trend reversal?

Sep 24, 2021 · Shares of Vir Biotechnology ( VIR -3.13%) were sinking 18.1% for the week as of the market close on Thursday. Vir was pulled down by the overall stock market sell-off earlier this week. However ...

What is the Vir stock price prognosis for 2026?

Mar 03, 2021 · VIR stock is plunging on some pretty unfavorable news about a trial being suspended for the company's prospective Covid-19 vaccine.

How often does walletinvestor update its vir stock predictions?

Feb 28, 2022 · Why did Vir Biotechnology stock drop today? Vir Biotechnology ( VIR -9.0%) the maker of COVID-19 antibody therapy sotrovimab is trading lower for the second consecutive session on Monday. Aside ...

See more

May 02, 2022 · Vir Biotechnology (VIR) Stock Sinks 11% as FDA Suspends the Use of Sotrovimab Against COVID-19 investing.com - April 5 at 6:13 PM FDA pulls approval for Vir Covid drug, …

Why is VIR going down?

Is VIR a good stock to buy?

Will VIR stock go up?

Is VIR biotechnology a buy?

Who owns VIR biotechnology?

How do I buy VIR stock?

Is Nautilus biotechnology a good stock to buy?

Is VIR losing hope?

All hope is not yet lost with VIR. However, investors can expect this stock to trade similar to an option in the coming weeks. Thus, I expect the heightened possibility of extreme volatility to keep most investors on the sidelines for now.

Is Vir Biotechnology a volatile stock?

A speculative bet on the race to develop a Covid-19 vaccine, VIR Biotechnology (NASDAQ: VIR) has been a highly volatile stock in recent months. Shares of VIR stock are down more than 30% at the time of writing. Additionally, investors should note this is a stock that is down nearly 75% from its all-time highs seen earlier this year.

Who is the CEO of Vir Biotechnology?

Our Most Admired CEO George Scangos, president and CEO of Vir Biotechnology Inc., along with his staff doubled down on their efforts during the pandemic to produce a drug with GlaxoSmithKline to treat Covid-19 patient.

Is Eli Lilly halting distribution?

The U.S. government said this week it is halting distribution of Eli Lilly & Co.'s COVID-19 antibody treatment in six states due to the growing prevalence of the P.1 and B.1.351 variants there. Lilly's combination therapy of bamlanivimab and etesevimab "are not active against either the P.1 or B.1.351 variants," which were first identified in Brazil and South Africa, respectively, the Assistant Secretary for Preparedness and Response said Wednesday. Coronavirus cases associated with these variants now make up more than 10% of all cases in Arizona, California, Florida, Illinois, Indiana, Massachussetts, Oregon, and Washington. Instead, the agency recommends using Regeneron Pharmaceuticals Inc.'s antibody treatment. This is not the first time there has been concern about bamlanivimab's effectiveness. The Food and Drug Administration in April pulled the emergency authorization for bamlanivimab as a standalone treatment over concerns about its effectiveness against variants. There are three authorized antibody cocktails in the U.S., developed by Lilly, Regeneron, and Vir Biotechnology Inc. /GlaxoSmithKline . The Vir and GSK therapy was authorized earlier this week.

Is Vir Biotechnology in Phase 2?

Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection. The results were presented at the European Association for the Study of the Liver International Liver Congress 2021. Data demonstrated an encouraging safety profile and the potential durable response of VIR-2218, an investigational small interfering ribonucleic acid, through 48 weeks. In a separate analy

Is Vir Biotechnology under pressure?

Shares of Vir Biotechnology (NASDAQ: VIR) are under pressure after the company's third-quarter earnings report. Investors unimpressed with the biotech's progress selling a COVID-19 treatment pushed the stock 14.9% lower as of 2:18 p.m. on Friday. Vir Biotechnology reported significant progress increasing access to sotrovimab, an intravenously administered antibody treatment the Food and Drug Administration authorized in May. In partnership with GlaxoSmithKline (NYSE: GSK), Vir Biotechnology has secured binding agreements for the sale of 420,000 doses of sotrovimab worldwide.

Is sotrovimab approved for emergency use?

GlaxoSmithKline plc and Vir Biotechnology Inc. said the U.S. Food and Drug Administration has granted emergency use authorization to its single-dose monoclonal antibody treatment sotrovimab in mild-to-moderate COVID-19 in adults and pediatric patients who are at high risk of severe illness, including hospitalization or death. Vir Chief Executive George Scangos said an interim analysis of data produced in a laboratory found the antibody treatment showed an 85% reduction in all-cause hospitalizations or death and is effective against all known variants of concern, including the emerging variant from India. The companies are still conducting clinical trials of the treatment and expects to provide analysis of safety and efficacy data at day 29 as early as the first half of 2021 and plan to submit a Biologics License Application (BLA) to the FDA in the second half of 2021.

When Might Vir Biotechnology Run Out Of Money?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. In September 2019, Vir Biotechnology had US$320m in cash, and was debt-free. In the last year, its cash burn was US$130m. That means it had a cash runway of about 2.5 years as of September 2019. Arguably, that's a prudent and sensible length of runway to have.

How Well Is Vir Biotechnology Growing?

At first glance it's a bit worrying to see that Vir Biotechnology actually boosted its cash burn by 39%, year on year. And we must say we find it concerning that operating revenue dropped 4.0% over the same period. Taken together, we think these growth metrics are a little worrying.

Can Vir Biotechnology Raise More Cash Easily?

While Vir Biotechnology seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business.